证券日报网讯1月27日，成都先导在互动平台回答投资者提问时表示，成都先导作为拥有全球已知最大 的DNA编码小分子实体化合物库的药物研发公司，业务广泛覆盖北美、欧洲、亚洲及大洋洲等主要医 药研发市场。2020年底，通过对英国Vernalis公司的收购，公司进一步拓展了欧洲市场。Vernalis深耕 FBDD/SBDD技术领域近30年，不仅是公司位于剑桥的重要研发中心，也承担了欧洲地区商务拓展、客 户关系维护及部分项目交付的职能，实现了研发与商业的协同。此外，公司也会根据客户与项目的具体 情况，灵活采用由境内主体直接对接或与其他合作伙伴协作的方式开展业务。 ...

智通财经APP讯，成都先导(688222.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润为1.04亿元到1.27亿元，与上年同期相比，将增加5,264.29万元到7,564.29万元，同比增加102.50% 到147.29%。 ...

证券日报网讯1月26日，百诚医药（301096）在互动平台回答投资者提问时表示，公司将依托自身在医 药研发领域的技术积累和产业化能力，与国科大杭高院的科研优势相结合，积极推进芳香胺等前沿技术 在产业端的应用。 ...

Market Overview - On January 23, Hong Kong stocks opened higher and fluctuated upwards, with the Hang Seng Index rising by 119 points (0.5%) to close at 26,749 points[1] - The Hang Seng Tech Index increased by 35 points (0.6%), closing at 5,798 points, with total market turnover reaching HKD 240.9 billion[1] - Southbound capital experienced a net outflow of HKD 1.6 billion[1] Regulatory Concerns - Chinese regulators are considering tightening the standards for mainland companies issuing shares in Hong Kong due to concerns over the quality of listed companies[1] - Potential measures may include setting a minimum market capitalization requirement for companies applying to list H-shares in Hong Kong[1] Sector Performance - The technology sector showed signs of recovery, with Alibaba (9988 HK) rising by 2.2%, Xiaomi (1810 HK) by 2.8%, and Kuaishou (1024 HK) by 2.7%[1] - The photovoltaic sector surged, with Xinyi Solar (968 HK) increasing by 11.1% and Fuyao Glass (6865 HK) by 10.4% following Tesla CEO Elon Musk's support for space photovoltaics[1] U.S. Market Dynamics - In the U.S., geopolitical tensions and conservative earnings guidance from Intel (INTC US) led to a decline in the Dow Jones Index by 285 points (0.6%) to 49,098 points[2] - The Nasdaq Index rose by 65 points (0.3%) to 23,501 points, while the S&P 500 Index increased by 2 points to 6,915 points[2] - Intel's stock fell by 17% due to supply constraints, while Nvidia (NVDA US) rose by 1.5% on news of Chinese approval for large tech firms to purchase H200 chips[2] Automotive Sector Highlights - The smart driving sector performed well, with Tesla's FSD system set to launch in China next month[3] - GAC Aion and Didi's Robotaxi R2 officially began mass production, and Cao Cao Mobility (2643 HK) plans to deploy 100,000 custom Robotaxis by 2030, with its stock rising by 10.2%[3] Healthcare Sector Insights - The Hang Seng Healthcare Index fell by 2.8% last week but rose by 1.1% on Friday[4] - Insilico Medicine (3696 HK) saw a rise after receiving FDA approval for its oral NLRP3 inhibitor for Parkinson's disease treatment[4] - Crystal Technology (2228 HK) reported significant advancements in CAR-T therapy, achieving a 100% complete response rate in lupus patients[4]

证券时报记者 王小芊 近日，银河基金的医药、周期、新能源、传媒和科技等领域的五位基金经理集中发声，围绕各自关注的投资方向 分享了最新观点。 尽管所处赛道不同，但在人工智能这一关键变量上，医药基金经理方伟、周期基金经理金烨、新能源基金经理李 一帆、传媒基金经理卢轶乔以及科技基金经理高鹏形成了高度一致的看法：AI正成为影响行业效率提升与估值逻 辑重构的重要背景因素。 AI角色正在转变 2026年，市场关注点正从是否具备AI概念，转向AI能否真正改变企业的盈利模型。这意味着，AI在投资层面的定 位，正在由情绪驱动的主题炒作，逐步走向可被纳入财务模型、估值重估的变量。 方伟指出，AI并不是一个独立于现有产业的新赛道，而更像是一种生产力工具，其核心价值在于对企业效率结构 的改造。在医药等行业中，AI的影响并不体现在短期收入爆发，而是通过提升研发效率、优化流程、降低费用 率，进而改变企业的利润率中枢与长期估值假设。一旦AI能够实质性影响费用率、利润率等关键参数，其投资逻 辑就有望进入可以量化、可以建模的阶段。 在应用端，卢轶乔认为，2026年有望成为AI应用系统性落地的元年，而非零星突破态势的延续。一方面，大模型 能力本 ...

Group 1 - Zhejiang Wenchuang Internet focuses on digital marketing and cultural technology, integrating AI into smart marketing and digital content creation, enhancing brand marketing digital transformation across various industries [1][17] - Saiwu Technology collaborates with Suzhou University to establish the AI4S laboratory, creating a closed loop of "AI screening - process optimization - mass production," significantly increasing revenue in related businesses [1][18] - Huashi Technology strategically invests in Yuchuang Robotics, applying AI in various scenarios such as airport monitoring and risk warning, providing intelligent solutions for smart cities [1][19] Group 2 - Yidian Tianxia leverages AI for global smart marketing, developing a full-chain solution that includes multi-language digital content generation and intelligent ad optimization [2][18] - Tongda Hai builds a comprehensive legal knowledge graph using vast legal data, enhancing judicial efficiency through its self-developed AI platform [2][19] - Sanwei Communication's subsidiary, Juwang Technology, utilizes AI for advertising material generation and optimization, significantly improving marketing efficiency [2][19] Group 3 - BlueFocus is a leader in AI marketing, applying AI across the entire marketing chain, including creative generation and effect analysis, to drive digital transformation in the marketing industry [3][19] - Huashu Media actively promotes AI integration in broadcasting, enhancing user experience through smart content recommendations and network optimization [3][20] - Subot constructs a cross-disciplinary platform for material and intelligent mechanics, driving high-end material development and optimizing production processes [3][20] Group 4 - Shiji Tianhong integrates AI into education, enhancing digital transformation in educational support services through intelligent systems [4][20] - Hongbo Pharmaceutical's AI drug design platform focuses on cyclic peptide drug development, significantly improving drug design efficiency and accuracy [5][21] - Tianlong Group's self-developed platform empowers digital marketing across various industries, enhancing customer acquisition and conversion rates [5][21] Group 5 - Yanshan Technology integrates AI into internet services and supply chain management, optimizing marketing and operational efficiency [6][22] - ChaoTu Software merges AI with GIS, enabling intelligent spatial data processing and analysis for smart city applications [6][22] - Heren Technology focuses on smart healthcare, developing AI systems to assist medical personnel and improve operational efficiency [6][23] Group 6 - Youzu Network applies AI throughout game development and operation, enhancing player engagement and experience [6][23] - Jinka Intelligent integrates AI into gas metering, improving management efficiency and safety in gas supply [7][24] - Liard incorporates AI into display technology, optimizing visual experiences and expanding applications in smart displays [7][24] Group 7 - Guanshang Technology focuses on military equipment lifecycle management using AI for fault diagnosis and training simulation [7][25] - Zhidema applies AI in consumer decision-making and e-commerce marketing, enhancing product recommendations and marketing strategies [7][25] - Runda Medical enhances laboratory testing processes with AI, improving detection accuracy and efficiency [7][25] Group 8 - Tiandi Online specializes in digital marketing, utilizing AI for user profiling and intelligent ad targeting [8][26] - Qianfang Technology focuses on smart transportation, developing AI systems for traffic management and vehicle recognition [8][26] - Jiaxun Feihong integrates AI into communication and rail transit, enhancing operational efficiency and safety [8][26] Group 9 - Jiadu Technology applies AI in smart city and rail transit, enhancing safety monitoring and automation [8][27] - Jiuzhoutong empowers pharmaceutical supply chains with AI for demand forecasting and inventory management [8][27] - Weining Health focuses on comprehensive smart healthcare solutions, enhancing operational efficiency and cost control [8][27] Group 10 - Dianke Digital strengthens IT service capabilities with AI, focusing on data center operations and security [8][28] - Guangting Information specializes in intelligent connected vehicles, developing AI systems for driving assistance and data governance [8][28] - Rongxin Culture integrates AI into children's publishing, enhancing reading experiences and content creation [8][29] Group 11 - Zhaochi Co. introduces AI in consumer electronics and lighting, optimizing product performance and supply chain management [8][29] - Jinxiandai focuses on industrial software, enhancing digital transformation through AI-assisted development and operations [8][30] - Huatu Shanding integrates AI into architectural design, improving efficiency and precision in building projects [8][30] Group 12 - Lakala enhances payment services with AI, improving transaction security and merchant support [8][30] - Yingjianke focuses on building design software, utilizing AI for structural optimization and efficiency [8][30] - Borui Communication empowers media and digital culture with AI, enhancing content delivery and user engagement [8][31] Group 13 - Haoyun Technology enhances security IoT with AI, providing risk assessment and decision support [8][31] - Shenguang Group leverages AI for digital marketing, optimizing user targeting and ad performance [8][31] - Oriental Pearl actively promotes AI in broadcasting, enhancing content production and user experience [8][31] Group 14 - Zhizhen Technology focuses on IT operations in communication and government sectors, utilizing AI for efficient management [8][32]

Core Insights - The core viewpoint emphasizes China's clear national strategy focusing on modernizing its industrial system, with technology and openness being paramount [1][14]. Strategic Industry Development - In the next five years, key industries for development include high-tech AI sectors, particularly embodied intelligence and physical AI [4][17]. - The pharmaceutical research and healthcare sector is projected to see significant growth, with 30% of global new drug pipelines expected to be from China by 2025 [5][18]. - The energy transition sector is highlighted as crucial, with China being a major consumer and contributor in the renewable energy field [6][19]. Opportunities for Chinese Enterprises Abroad - Eastern and Central Eastern Europe are identified as attractive regions for Chinese enterprises due to cost advantages and proximity to EU markets [8][20]. - In mature European markets like Germany, Chinese automotive companies, especially in the new energy vehicle sector, are focusing on expansion [8][20]. - The concept of "glocalization" is emphasized, where companies must adapt to local markets while maintaining global strategies [8][20]. Stages of Globalization for Chinese Enterprises - The current phase of Chinese enterprises going global is termed "Outward 3.0," which integrates technology, supply chain, and management capabilities [11][23]. - Previous phases included "Outward 1.0," focused on product trade, and "Outward 2.0," which involved establishing factories and supply chains abroad [11][23]. - The need for proactive risk management and local integration is stressed to enhance the value of Chinese enterprises in global markets [9][21][23].

Core Viewpoint - The company has developed an AI platform for drug research that enhances the precision and efficiency of drug development processes [2] Group 1: AI Platform - The AI platform, referred to as the "Smart Drug AI Platform," is capable of predicting toxicity, activity, and drug-likeness [2] - This platform aims to improve the accuracy and efficiency of drug development [2] Group 2: New Drug Department - The new drug department utilizes an organoid platform that offers drug screening, efficacy evaluation, and safety assessment services [2] - These services are designed to support more precise and efficient drug research [2]

Core Insights - The conference held by Yaoshi Technology Group focused on the integration of AI in the pharmaceutical industry, aligning with national strategies for high-quality development and innovation in biomedicine [1][5] - The event gathered over a hundred participants, including executives and industry partners, to discuss AI's role in drug development, smart manufacturing, and CRDMO services [1][5] Group 1: Company Strategy - Dr. Yang Minmin, the founder and CEO, emphasized that AI empowerment is the core driving force for industry competition and highlighted the need for accurate data and streamlined business processes for successful transformation [3][4] - The company aims to lead sustainable development through green and intelligent chemical innovations, establishing dual platforms for smart R&D and manufacturing [3][4] Group 2: AI Implementation - The Chief Information Officer, Dr. Liu Heping, outlined a three-phase AI strategy: short-term foundation building, mid-term integration, and long-term leadership, focusing on data and AI as core components [4] - Solutions for drug development challenges were presented, including knowledge graph target validation and generative AI for molecular screening, creating a closed-loop DMTA system [4] Group 3: Industry Trends - Industry partners shared insights on AI's transformative impact across the pharmaceutical supply chain, highlighting advancements in decision-making, safety, efficiency, and cost reduction [5] - The conference established a consensus that AI transformation is essential, with a clear path for implementation focusing on data foundation, scenario prioritization, and ecosystem collaboration [5]

Core Viewpoint - Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. has voluntarily disclosed its 2025 annual performance forecast, indicating a positive growth trajectory in revenue and profit for the upcoming year [2][10]. Performance Forecast - The expected operating revenue for 2025 is projected to be between 1,192.45 million yuan and 1,371.32 million yuan, representing a year-on-year increase of 10.57% to 27.15% [2]. - The anticipated total profit for 2025 is estimated to be between 195.79 million yuan and 234.94 million yuan, reflecting a year-on-year growth of 11.25% to 33.50% [2]. - The net profit attributable to the parent company is forecasted to be between 191.05 million yuan and 229.26 million yuan, indicating a year-on-year increase of 7.69% to 29.23% [2]. - The net profit after deducting non-recurring gains and losses is expected to be between 179.70 million yuan and 215.64 million yuan, with a year-on-year growth of 8.84% to 30.61% [2]. Previous Year Performance - In the previous year, the operating revenue was 1,078.47 million yuan [4]. - The total profit was 175.99 million yuan, and the net profit attributable to the parent company was 177.41 million yuan [4]. - The net profit after deducting non-recurring gains and losses was 165.11 million yuan [4]. Reasons for Performance Changes - The company's revenue and profit are expected to grow steadily due to the deepening layout of its innovative drug pipeline, realization of value from authorized collaborations, and synergistic support from its integrated service model [6]. - The focus on innovative drug research and development, particularly in areas with global intellectual property rights, has led to a pipeline matrix that includes over 20 first-class new drugs targeting major diseases [6]. - The integration of AI technology with unique technical platforms has further enhanced the company's core competitiveness, facilitating rapid advancement of its research pipeline [6][7]. - Authorized collaborations and revenue sharing have become key drivers of profit growth, with significant income generated from the licensing of pipelines like STC007 and STC008 [7].